Canada greenlights Moderna Ebola vaccine trials

Canada has granted approval to the American pharmaceutical giant Moderna to begin clinical trials of a vaccine against the Bungibugo strain of the Ebola virus, as part of a response to the outbreak that has claimed the lives of over 1,700 people in the Democratic Republic of Congo since May. The first phase of the trials will assess the safety of the vaccine and determine the range of safe dosages, with a focus on generating antibodies against the new strain, as no cases of Ebola have been recorded in Canada to date. The trials require additional phases using messenger RNA technology, and efforts are underway to develop other vaccines, such as the University of Oxford’s vaccine, which employs a similar technique to the flu vaccine, while ongoing medical treatment trials continue in accordance with the World Health Organization.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل